Project Grant R43CA298515
Award Date
8/1/25
Completion Date
7/31/26
Dollars Obligated
$406K
Federal Agency
National Cancer Institute
Federal Grant Program
93.394
Assistance Type
Project Grant
Place of Performance
Farmington, CT 06032, USA
Similar Awards
This Project Grant award, titled "Optical Hyperspectral Nanoscale Chromatin Analysis for Colon Cancer Risk-Stratification", is funded by the National Cancer Institute (NCI) under CFDA 93.394 Cancer Detection and Diagnosis Research program. The $670,534 award to Northwestern University aims to develop a screening test to identify patients who harbor advanced adenomas and would benefit from colonoscopy, a crucial step in preventing colorectal cancer, the second leading cause of cancer...
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), will support the development and clinical validation of an Optical Coherence Tomography (OCT) system and two specialized OCT imaging probes to enhance colorectal cancer screening. The $1,471,777 award to The General Hospital Corporation (doing business as Massachusetts General Hospital) aims to create an OCT system that can obtain 3D microscopic images of...
This Cooperative Agreement award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $1,280,475.00 to The Leland Stanford Junior University to develop a novel approach for early detection of colorectal cancer using cell-free DNA (cfDNA) methylation profiles. The key objectives are to: (1) characterize the early-stage colorectal cancer cfDNA methylome landscape, and (2) develop a machine learning model to detect early-stage colorectal cancer from...
The National Cancer Institute (NCI) awarded a $1,280,908 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to Exai Bio Inc., a small disadvantaged business in Palo Alto, California. The grant supports the development of a novel assay and artificial intelligence (AI) model for early detection of non-small cell lung cancer (NSCLC) and predicting its subtypes using orphan non-coding RNA (oncRNA) biomarkers. The goal is to create a liquid biopsy-based diagnostic...
The National Cancer Institute (NCI) awarded a $962,560 Project Grant (CFDA 93.394 - Cancer Detection and Diagnosis Research) to Basic Health International Inc., a non-profit organization in Pittsburgh, Pennsylvania. The grant aims to modify and clinically validate the IRISTM device, a handheld thermal ablation device and digital colposcope designed for cervical cancer screening and treatment in low- and middle-income countries (LMIC). The key goals of the project are to: 1) Modify the IRISTM...
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) supports the development of a novel circulating tumor DNA (ctDNA) assay technology by Binary Genomics, Inc. to monitor the efficacy of immunotherapy treatments for non-small cell lung cancer. The $398,040 award over 18 months will enable the company to evaluate the analytical and baseline clinical performance of their ctDNA assay, which aims to address limitations of existing...
The National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) awarded a $399,998 Project Grant to Darwin Biosciences, Inc. to develop a low-cost, handheld, and non-invasive lung cancer screening device for use in low-resource settings. The goal of this 1-year Phase I project is to adapt Darwin Biosciences' existing platform, which was developed under a separate DoD contract, to detect circulating tumor DNA biomarkers for non-small cell lung cancer using saliva and...
This federal Project Grant award, totaling $592,866, was provided by the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) to Georgia Tech Research Corporation to develop ingestible nanosensors for the breath-based detection of colorectal cancer. The key objectives of this 5-year project are to engineer ingestible nanosensors that can sense specific enzymes in the intestinal tract associated with colorectal cancer development and release volatile reporter...
This federal Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) provides $1,043,109 to Isono Health, Inc. to develop and validate artificial intelligence (AI) models for its ATUSA 3D breast ultrasound imaging platform. The goal is to create lesion classification, lesion segmentation, and breast density calculator AI models to improve the ATUSA system's ability to accurately identify and diagnose breast cancer at an...
This National Cancer Institute (CFDA 93.396 Cancer Biology Research) Project Grant award of $560,297 to the Icahn School of Medicine at Mount Sinai supports research to functionally characterize oncofetal stem cells (ONFSCs) in colorectal cancer (CRC). The key objectives are to: Generate phenotypic transcriptional reporters to track the dynamics of LGR5+ cancer stem cells (CSCs) and ONFSCs, and use these to dissect the functional interplay between these stem cell populations. Employ a multi-omic...